ArticleMolecular cancer therapeutics2024

Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination.

Alison D Parisian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.